When the news broke December 5 that an FDA expert panel had voted 5-4 to reject Avastin (bevacizumab) as an approved breast cancer treatment because of serious side effects, I experienced a moment of deep sadness, as well as some frustration. Avastin, a cutting-edge, “targeted drug” therapy for women with metastatic breast cancer, has been shown (when taken with chemotherapy) to give these women an extra 5 1/2 months of time when their cancer doesn’t grow and spread. And when you have...

